What Levosol (Levodropropizine) Treats: Main Uses and Benefits

Levosol is commonly used for symptomatic relief, offering supportive assistance when symptoms become temporarily overwhelming or disrupt daily life. The medication is relevant in contexts marked by increased discomfort and is commonly used for managing the non-productive (dry) cough component in various conditions.

It is applied in clinical settings that involve cough symptoms associated with acute bronchitis, Upper Respiratory Tract Infections (URTIs), and may be relevant in cases of chronic bronchitis. It is used for managing symptom clusters that may become intense or disruptive, aligning with established therapeutic applications for this active ingredient. Symptomatic relief helps improve day-to-day comfort by addressing nocturnal awakenings caused by coughing, assisting with maintaining functional stability.

“Symptomatic relief is considered relevant for easing the intensity and frequency of dry coughing, helping patients cope more steadily with difficult episodes.”

---

Quick Fact: Symptomatic Support for Non-Productive Cough
Primary Symptom Targeted	Dry, irritating cough (non-productive)
Core Patient Benefit	Contributes to easing the overall symptom load related to sleep and function
Common Clinical Contexts	Acute bronchitis, URTIs, and chronic bronchitis (non-expectorant component)

Regulatory References

1. ClinicalTrials.gov on Levodropropizine's use

Who Can and Cannot Use Levosol (Levodropropizine)?

The eligibility for Levosol (Levodropropizine) is strictly defined by government regulatory documents, focusing on absolute prohibitions and conditional use.

Populations for Whom Use is Contraindicated

Use is contraindicated and must be avoided in the following groups:

Population Group or Condition	Status
Children below 2 years of age	Contraindicated
Pregnancy and Lactation (Breastfeeding)	Contraindicated
Hypersensitivity to levodropropizine or excipients	Contraindicated
Bronchorrhea (excessive bronchial secretions)	Contraindicated
Reduced Mucociliary Function (e.g., Kartagener syndrome)	Contraindicated
Severe Hepatic Impairment	Contraindicated

Approved and Restricted Populations

Levosol is authorized for use in adults and children over 2 years of age under standard labeled conditions.

Regulatory warnings define restricted use in special populations:

• Severe Renal Impairment (creatinine clearance < 35 ml/min): The medicine must be used cautiously, and the benefit-risk ratio must be taken into consideration by a physician.
• Older Adults (Geriatric): Caution is required and special consideration should be given due to potential age-related changes in the drug's processing.
• Hereditary Metabolic Disorders: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency must avoid the syrup formulation due to its sugar content.

Levosol’s official interaction profile, based on government regulatory documentation, focuses primarily on pharmacodynamic potentiation and specific administration constraints.

Interactions with CNS Depressants and Alcohol

Co-administration with other substances that act on the central nervous system (CNS) requires regulatory caution due to the potential for additive CNS depressant effects. This risk is documented for medicinal product categories such as sedative drugs, hypnotics, and sedating antihistamine drugs. The resulting interaction may increase effects like drowsiness. This need for careful administration is specifically noted in regulatory texts for particularly sensitive individuals. Furthermore, the concurrent consumption of alcohol is documented to have the potential to intensify these CNS depressant effects. No drug-drug combinations are formally classified as contraindicated.

Pharmacokinetic and Timing Constraints

The official prescribing information does not document any clinically significant interactions that alter systemic exposure. Specifically, the regulatory profile states no interactions mediated by the CYP450 enzyme system or drug transporters. This defines an interaction profile that is not driven by metabolic clearance changes. A specific timing constraint is noted regarding meals: an advisory separation from meals is recommended, as conclusive data on the effect of food on drug absorption is not available in official documentation.

Levodropropizine functions as a peripherally acting modulator, primarily targeting the afferent arm of the cough reflex arc within the tracheobronchial tree and upper respiratory tract. Its action is centered on the sensory nerve endings, particularly the unmyelinated vagal C-fibers. The compound acts as an inhibitor by directly decreasing the excitability of these peripheral receptors.

Downstream of C-fiber activation, Levodropropizine exerts an inhibitory modulation on the local release of sensory neuropeptides, notably Substance P. By reducing the concentration of these key signaling molecules at the nerve terminals, the propagation of afferent impulses toward the medullary cough center is suppressed. This system-level physiological modulation results in a decreased sensitivity of the peripheral cough receptors to stimuli and a subsequent functional dampening of the reflex arc. Furthermore, the compound exhibits antihistaminic properties and an inhibitory action against bronchospasm induced by endogenous mediators such as histamine, serotonin, and bradykinin.

How to Use Levosol (Levodropropizine) — Official Administration Guidelines

The administration of Levodropropizine is restricted to the oral route, typically supplied as an oral solution (syrup) or tablets. Specific parameters are established for dosing frequency and duration across different age groups.

---

Dosing and Frequency

For adults and adolescents over 12 years of age, the standard single dose is 60 mg. This dose may be administered up to three times daily, provided that an interval of at least 6 hours is strictly maintained between administrations. The maximum total daily intake is restricted to 180 mg. To ensure proper administration, oral liquid forms are to be measured using a dosing device.

Regarding the timing of intake, the medication is generally taken away from meals or between meal times.

---

Population-Specific Use and Duration

Use of the medication is not recommended for children under 2 years of age. For children between 2 and 12 years, the prescribed dosage is weight-dependent, typically established at 1 mg per kilogram of body weight for a single dose, also administered up to three times daily.

The duration of treatment for all patients must be limited; use should not extend beyond 7 consecutive days. Treatment should be discontinued as soon as the cough symptom is resolved. Caution is advised when administering the drug to older adults and to patients with severe renal impairment (creatinine clearance < 35 ml/ min).

Research Evidence: Evaluating Non-Productive Cough Relief

Evidence for Use in Acute Respiratory Illness (ARI)

The clinical evaluation for use in acute dry cough is primarily based on short-term, randomized controlled trials (RCTs) and subsequent scientific reviews. This research examined non-productive cough in adults and pediatric patients (typically ages two and up) experiencing conditions characterized by fluctuating or episodic manifestations, such as those associated with acute bronchitis. The outcomes related to physical discomfort that were studied included the measured frequency and intensity or variability of the cough.

Studies observed patterns where the measured frequency and severity of cough evolved over the short study period, which usually lasted between three and seven days. Findings describe patterns observed in the studies related to a change in the measured amount of cough activity, both during daytime hours and concerning nocturnal awakenings. The research focuses on short-term symptom changes, meaning follow-up durations were limited.

Research Focus on Specific Patient Groups

Research has explored the use of Levosol in specific groups, including pediatric patients, using dedicated randomized trials. The primary outcomes studied in children included the frequency of coughing spells and the number of nocturnal awakenings due to cough. Findings describe patterns where pediatric patients' symptoms evolved, with changes observed over the short, acute treatment course.

Physiological studies have also been conducted to understand if the agent acts on the central nervous system. Studies reported no substantial change in measured ventilatory response when compared to placebo, findings that align with its pharmacological classification as a peripherally-acting agent.

What Remains Uncertain in the Research Landscape

Key research limitation frames include the duration of studies; the evidence is derived from studies focused on short-term symptom changes (3 to 7 days). There is limited information for long-term outcomes, as trials were not designed to monitor use over extended periods. While research exists for acute cough, data are still emerging regarding its application across all possible patient subgroups, and evidence quality varies across studies, with studies for chronic cough having modest sample sizes.

Key Studies & References

1. Efficacy of levodropropizine in the treatment of cough in children: a systematic review and meta-analysis of randomized controlled trials.
2. Assessment of the clinical efficacy and safety of levodropropizine in the symptomatic treatment of cough in pediatric patients: A double-blind, randomized, placebo-controlled study.

Common questions about Levosol (Levodropropizine) (FAQ)

Q: Does it make you sleepy? Can I drive after taking it?

Official product information indicates that this medicine may cause somnolence, which is the medical term for drowsiness, or dizziness in some individuals. Because of this possibility, official documents suggest exercising caution regarding activities that require alertness, such as driving vehicles or operating machinery, if these effects are experienced. This is based on potential effects on the central nervous system.

Q: How long does it take to start working, and how long does it last?

Official information from pharmacokinetic studies shows that Levodropropizine is rapidly absorbed after it is taken orally. The highest concentration of the drug in the blood is typically reached within 15 to 45 minutes (0.25 to 0.75 hours) after the dose. The half-life of the compound in the body, which is the time required for the amount of drug to be reduced by half, is described as being approximately one to two hours.

Q: Can I take it with paracetamol or ibuprofen?

Regulatory documents state that clinical trials examining this medicine have not demonstrated any interactions with other common drugs used for bronchopulmonary conditions. While regulatory information does not list specific interactions with common painkillers like paracetamol or ibuprofen, caution regarding the potential for additive effects is noted for use alongside central nervous system sedative drugs.

Q: Can I take this if I have high blood pressure or diabetes?

High blood pressure is not listed in the regulatory documents as a specific warning or contraindication for use. However, if you are using the syrup formulation, official precautions note that its sucrose content must be considered by patients who have diabetes mellitus. This consideration is specific to the inactive ingredients found in the liquid formulation.

Q: Is it safe to use for a long time (more than a week or two)?

According to official regulatory documents, the maximum duration for this treatment should not exceed seven consecutive days. The recommendation is to continue treatment until the cough has resolved. If the cough persists beyond this one-week period, patients may need to consult their healthcare provider.

Q: Does the syrup contain parabens or other preservatives?

Yes, the syrup formulation contains the excipients methyl para-hydroxybenzoate and propyl para-hydroxybenzoate, which are types of parabens. Official documentation notes that these ingredients may cause allergic reactions, including the possibility of delayed reactions.

Q: What are the symptoms of an overdose?

Regulatory information on overdose suggests that patients may experience a mild, temporary tachycardia, which is a rapid heart rate. In addition, reports have documented abdominal pain and vomiting following intake exceeding the recommended amount.

Storage and Disposal of Levosol (Levodropropizine)

The official labeling defines specific constraints for storing and disposing of Levosol to maintain its stability and ensure safety.

Storage Requirements

Temperature and Protection: The medicine must be stored at room temperature, typically below 30°C or 25°C, and must be protected from light. It should remain in the original bottle pack and must be kept out of the sight and reach of children.

Stability Limit: The Levosol oral solution has a limited in-use shelf life; it must be discarded after one month of opening.

Disposal

Unused or expired Levosol must be disposed of in accordance with local regulations. It should not be thrown away via wastewater or household waste unless local guidelines specifically permit it. No special hazardous waste handling is required.